Jeanine M.L. Roodhart

Patient-reported quality of life after chemoradiotherapy in patients with non-metastatic anal squamous cell carcinoma: A cross-sectional cohort study

R.A. Lunenberg, F. van Erning, F.P.C. Sijtsma, I.H.J.T. de Hingh et autres

BACKGROUND AND PURPOSE: For most patients with non-metastatic anal squamous cell carcinoma (ASCC), chemoradiotherapy (CRT) is the standard treatment. Data on long-term health-related quality of life (HRQoL) following CRT are limited. This study evaluated HRQoL and functioning of patients with ASCC after …

nl (code pays fourni par la source)

Real-world patient-reported outcomes in stage II/III rectal cancer in the Netherlands.

R.A. Lunenberg, Frederieke H. van der Baan, Ingrid A. Franken, Femke P.C. Sijtsma et autres

65 Background: In a real-world (RW) study, tumor characteristics and outcomes differed between patients (pts) with mismatch repair deficient (dMMR) and proficient (pMMR) stage II/III rectal cancer (RC) from the Netherlands 1 . To address the scarcity of quality-of-life (QoL) data, particularly …

nl, us (code pays fourni par la source)

A feasibility analysis to align fit-for-purpose real-world (RW) data to emulate the AZUR-1 single-arm clinical trial in patients (pts) with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) locally advanced rectal cancer (RC).

Jeanine M.L. Roodhart, Sean O’Donnell, Linda Kalilani, Eunice Hankinson et autres

70 Background: AZUR-1, a clinical trial (NCT05723562) evaluating dostarlimab for pts with dMMR/MSI-H stage II/III RC, has a single-arm design due to the rarity of dMMR/MSI-H in locally advanced RC, known clinical activity of dostarlimab, 1 and complications of the current multimodal …

nl, us, gb (code pays fourni par la source)

Real-world use of encorafenib plus cetuximab after prior systemic therapy in patients with BRAFV600E-mutant metastatic colorectal cancer: a pooled analysis of European observational studies

Chiara Cremolini, Julien Taı̈eb, Erika Martinelli, Ana Fernández Montés et autres

it, fr, es, nl, de (code pays fourni par la source)

Accelerating personalized medicine: Miniaturized patient-derived organoid drug screening for predicting cancer treatment responses and beyond

Yasmine Abouleila, Lidwien P. Smabers, Timo Voskuilen, Mayke Doorn et autres

nl, jp (code pays fourni par la source)

Circulating tumour DNA in patients with stage III colon cancer: multicentre prospective PROVENC3 study

Carmen Rubio-Alarcón, Andrew Georgiadis, Ingrid A. Franken, Haoyue Wang et autres

BACKGROUND: Circulating tumour DNA (ctDNA) is a promising biomarker to guide clinical decision-making. The aim of this study was to investigate the prognostic value of postoperative ctDNA in patients with stage III colon cancer who received adjuvant chemotherapy (ACT). METHODS: PROVENC3 was …

nl, us (code pays fourni par la source)

Supplementary Data 1 from Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer

Lidwien P. Smabers, G. Emerens Wensink, Carla S. Verissimo, Mayke Doorn et autres

Tables S1-S6 and Figures S1–S8

Table 1 from Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer

Lidwien P. Smabers, G. Emerens Wensink, Carla S. Verissimo, Mayke Doorn et autres

Baseline characteristics of the study population, with key demographic, clinical, and molecular details from regular diagnostic sequencing.

Figure 1 from Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer

Lidwien P. Smabers, G. Emerens Wensink, Carla S. Verissimo, Mayke Doorn et autres

Schematic overview of the study. Patients underwent a biopsy of a metastasis for PDO culture and WGS, before starting a new line of systemic treatment. Predictors of successful PDO establishment were identified: male sex, increased LDH, biopsy in academic hospitals, optimized culture …

Data from Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer

Lidwien P. Smabers, G. Emerens Wensink, Carla S. Verissimo, Mayke Doorn et autres

AbstractPurpose: Accurately predicting treatment response in metastatic colorectal cancer (mCRC) is critical to avoid unnecessary toxicity and improve patient outcomes. Patient-derived organoids (PDO) are promising models, but larger prospective studies are needed to confirm their predictive value. Experimental Design: Patients with mCRC …

Figure 2 from Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer

Lidwien P. Smabers, G. Emerens Wensink, Carla S. Verissimo, Mayke Doorn et autres

Clinical variables related to PDO establishment success: CEA, LDH, mutational status, sex, primary tumor sidedness, prior chemotherapeutic treatment, metastatic site of the biopsy, WGS success, and aggregated biopsy color (brown, pink, red, and white). CEA, carcinoembryonic antigen; mut, mutant.

Figure 3 from Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer

Lidwien P. Smabers, G. Emerens Wensink, Carla S. Verissimo, Mayke Doorn et autres

Genomic landscape of 36 tumors and/or PDOs derived from patients with mCRC. Top, microsatellite stability, tumor mutational load, tumor mutational burden, and whether the sequencing was performed on the PDOs or the tumor of origin; bottom, somatic driver mutations. MS, microsatellite status; …